[1]刘娇,程兵,常伟,等.非高危分化型甲状腺癌低剂量和高剂量131I清甲疗效的分析[J].国际放射医学核医学杂志,2016,40(6):419-423.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
　Liu Jiao,Cheng Bing,Chang Wei,et al.Ablation efficacy in non-high-risk differentiated thyroid carcinoma patients with low-dose and high-dose 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):419-423.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
点击复制

非高危分化型甲状腺癌低剂量和高剂量131I清甲疗效的分析(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
40
期数:
2016年第6期
页码:
419-423
栏目:
论著
出版日期:
2016-11-25

文章信息/Info

Title:
Ablation efficacy in non-high-risk differentiated thyroid carcinoma patients with low-dose and high-dose 131I
作者:
刘娇;  程兵;  常伟;  李祥周;  刘保平
450052, 郑州大学第一附属医院核医学科
Author(s):
Liu Jiao;  Cheng Bing;  Chang Wei;  Li Xiangzhou;  Liu Baoping
Department of Nuclear Medicine, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
关键词:
碘放射性同位素; 分化型甲状腺癌; 放射治疗剂量; 非高危; 清甲
Keywords:
Iodine radioisotopes; Differentiated thyroid carcinoma; Radiotherapy dosage; Non-high-risk; Thyroid remnant ablation
DOI:
10.3760/cma.j.issn.1673-4114.2016.06.004
摘要:
目的 研究应用低剂量（1.11 GBq）和高剂量（3.70 GBq）放射性131I清除非高危分化型甲状腺癌（DTC）术后残留甲状腺组织的疗效。方法 回顾性分析行131I清甲治疗的63例非高危DTC患者的临床资料，采用Binary Logistic回归分析年龄、首次手术距清甲的时间间隔、甲状腺24 h摄碘率、血清TSH水平和清甲剂量对清甲疗效的影响；27例患者给予低剂量、36例患者给予高剂量的131I清甲治疗，采用Pearsonχ2检验分析低剂量和高剂量131I清甲疗效的差异，P<0.05表示差异有统计学意义。结果 63例非高危DTC患者中，清甲成功者46例（73.02%，46/63）、未成功者17例（26.98%，17/63）；Binary Logistic回归分析显示，131I清甲剂量是清甲成功与否的主要影响因素（Wald=6.42，P=0.011）；27例给予低剂量131I清甲患者中有15例清甲成功，36例给予高剂量131I清甲者中31例清甲成功，Pearsonχ2检验结果表明，高剂量131I清甲成功率（86.11%，31/36）明显高于低剂量（55.56%，15/27）（χ2=7.311，P=0.007）。结论 在临床实践中，当残余甲状腺组织较少时，对于非高危DTC患者可考虑采用高剂量131I清甲治疗，提高一次清甲成功率。
Abstract:
Objective To investigate the efficacy of low-dose(1.11 GBq) and high-dose(3.70 GBq) radioactive 131I on residual thyroid tissues in patients after a non-high-risk differentiated thyroid carcinoma(DTC) resection. Methods Clinical data of a total of 63 patients with non-high-risk DTC who had experienced 131I therapy were analyzed retrospectively. Binary logistic regression was employed to analyze the effects of age, interval from initial resection to initial 131I ablation, rate of thyroid iodine uptake for 24 h, serum TSH level, and 131I dose on efficacy of thyroid remnant ablation. Out of 63 patients, 27 were given low doses while 36 patients were given high doses of 131I therapy. Pearson’s chi-square test was used to differentiate the efficacy of low-dose and high-dose 131I on residual thyroid tissues. P<0.05 was considered statistically significant. Results Among the 63 non-high-risk DTC patients, 46 patients achieved successful thyroid remnant ablation(73.02%, 46/63) but 17 failed(26.98%, 17/63). Binary logistic regression analysis indicated that the ablation dose of 131I was the main factor for the efficacy of ablation(Wald=6.42, P=0.011). Among the 27 patients who had low doses of 131I therapy, 15 achieved effective thyroid remnant ablation. However, 31 patients achieved effective thyroid remnant ablation after high doses of 131I therapy among 36 patients. Pearson’s chi-square test revealed that the ablation efficacy in patients with high-dose 131I(86.11%, 31/36) was higher than those with low-dose 131I(55.56%,15/27)(χ2=7.311, P=0.007). Conclusion In clinical practice, high-dose 131I on residual thyroid tissues should be considered for patients after non-high-risk DTC resection to improve the efficacy of 131I ablation at first dose when the volume of thyroid remnant tissues is low.

参考文献/References:

[1] dos SSI, Swerdlow AJ.Thyroid cancer epidemiology in England and Wales:time trends and geographical distribution[J].Br J Cancer, 1993, 67(2):330-340.
[2] Pettersson B, Adami HO, Wilander E, et al.Trends in thyroid cancer incidence in Sweden, 1958-1981, by histopathologictype[J].Int J Cancer, 1991, 48(1):28-33.
[3] 国兰兰, 高沁怡, 李亚明, 等.影响分化型甲状腺癌术后131I治疗疗效的因素[J].中国医学影像技术, 2011, 27(5):926-929.Gao LL, Gao QY, Li YM, et al.Impact factors of therapeutic effect of 131I scintigraphy treatment for differentiated thyroid cancer after operation[J].Chin J Med Imaging Technol, 2011, 27(5):926-929.
[4] Mallick U, Harmer C, Yap B, et al.Ablation with low-dose radioiodine and thyrotropinalfa in thyroid cancer[J].N Engl J Med, 2012, 366(18):1674-1685. DOI:10.1056/NEJMoa1109589.
[5] Schlumberger M, Catargi B, Borget I, et al.Strategies of radioiodine ablation in patients with low-risk thyroid cancer[J].N Engl J Med, 2012, 366(18):1663-1673. DOI:10.1056/NEJMoa1108586.
[6] 潘中允.放射性核素治疗学[M].北京:人民卫生出版社, 2006.Pan ZY.Radionuclide therapy[M].Beijing:People’s Medical Publishing House, 2006.
[7] 中华医学会核医学分会.131I治疗分化型甲状腺癌指南(2014版)[J].中华核医学与分子影像杂志, 2014, 34(4):264-278. DOI:10.3760/cma.j.issn.2095-2848.2014.04.002.Chinese Society of Nuclear Medical.131I treatment of differentiated thyroid carcinoma Directory(2014 Edition)[J].Chin J Nucl Med Mol Imaging, 2014, 34(4):264-278.
[8] Sciuto R, Romano L, Rea S, et al.Natural history and clinical outcome of differentiated thyroid carcinoma:a retrospective analysis of 1503 patients treated at a single institution[J].Ann Oncol, 2009, 20(10):1728-1735. DOI:10.1093/annonc/mdp050.
[9] Eustatia-Rutten CF, Corssmit EP, Biermasz NR, et al.Survival and death causes in differentiated thyroid carcinoma[J].J Clin Endocrinol Metab, 2006, 91(1):313-319. DOI:10.1210/jc.2005-1322.
[10] Baudin E, Schlumberger M.New therapeutic approaches for metas-tatic thyroid carcinoma[J].Lancet Oncol, 2007, 8(2):148-156. DOI:10.1016/S1470-2045(07)70034-7.
[11] Durante C, Haddy N, Baudin E, et al.Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma:benefits and limits of radioiodine therapy[J].J Clin Endocrinol Metab, 2006, 91(8):2892-2899. DOI:10.1210/jc.2005-2838.
[12] Mazzaferri EL, Kloos RT.Clinical review 128:Current approaches to primary therapy for papillary and follicular thyroid cancer[J].J Clin Endocrinol Metab, 2001, 86(4):1447-1463. DOI:10.1210/jcem.86.4.7407.
[13] Haugen BR, Alexander EK, Bible KC, et al.2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer:The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer[J].Thyroid, 2016, 26(1):1-133. DOI:10.1089/thy.2015.0020.
[14] 傅宏亮, 杜学亮, 顾振辉, 等.分化型甲状腺癌131I疗效影响因素分析[J].上海交通大学学报:医学版, 2010, 30(3):249-252.Fu HL, Du XL, Gu ZH, et al.Analysis of influential factors for efficacy of 131I thyroid remnant ablation for differentiated thyroid carcinoma[J].J shanghai Jiaotong Univ(Med Sci), 2010, 30(3):249-252.
[15] 刘晔, 晋建华, 刘建中, 等.放射性131I去除分化型甲状腺癌术后残留甲状腺组织的疗效与影响因素分析[J].中国药物与临床, 2013, 13(5):556-558. DOI:10.11655/zgywylc2013.05.003.Liu Y, Jin JH, Liu JZ, et al.Efficacy and influencing factors of radioactive 131I for elimination of thyroid remnants following differentiated thyroid carcinoma resection[J].Chin RemedClin, 2013, 13(5):556-558.
[16] Sánchez R, Espinosa-de-los-Monteros AL, Mendoza V, et al.Adequate thyroid-stimulating hormone levels after levothyroxine discontinuation in the follow-up of patients with well-differentiated thyroid carcinoma[J].Arch Med Res, 2002, 33(5):478-481.
[17] Liel Y.Preparation for radioactive iodine administration in differentiated thyroid cancer patients[J].Clin Endocrinol(Oxf), 2002, 57(4):523-527. DOI:10.1046/j.1365-2265.2002.01631.x.
[18] Mashego MR, Wu L, Van Dam JC, et al.MIRACLE:mass isotopomer ratio analysis of U-13C-labeled extracts.A new method for accurate quantification of changes in concentrations of intracellular metabolites[J].BiotechnolBioeng, 2004, 85(6):620-628. DOI:10.1002/bit.10907.
[19] 匡安仁.131I治疗分化型甲状腺癌[M].北京:人民卫生出版社, 2013.Kuang AR.131I treatment of differentiated thyroid carcinoma[M].Beijing:People’s Medical Publishing House, 2013.
[20] M?enp??HO, Heikkonen J, Vaalavirta L, et al.Low vs.high radioiodine activity to ablate the thyroid after thyroidectomy for cancer:a randomized study[J/OL].PLoS One, 2008, 3(4):e1885[2016-06-28].https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2270902/. DOI:10.1371/journal.pone.0001885.
[21] Schlumberger M, Catargi B, Borget I, et al.Strategies of radioiodine ablation in patients with low-risk thyroid cancer[J].N Engl J Med, 2012, 366(18):1663-1673. DOI:10.1056/NEJMoa1108586.
[22] Mallick U, Harmer C, Yap B, et al.Ablation with low-dose radioiodine and thyrotropinalfa in thyroid cancer[J].N Engl J Med, 2012, 366(18):1674-1685. DOI:10.1056/NEJMoa1109589.

相似文献/References:

[1]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
　Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[2]邓艳,张伟.125I-碘酞酸盐临床应用进展[J].国际放射医学核医学杂志,2016,40(3):225.[doi:10.3760/cma.j.issn.1673-4114.2016.03.012]
　Deng Yan,Zhang Wei.125I-iothalamate clinical applications[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):225.[doi:10.3760/cma.j.issn.1673-4114.2016.03.012]
[3]田琦,蒋宁一,郑丽.265例精细个体化131I治疗Graves甲亢的疗效观察[J].国际放射医学核医学杂志,2016,40(4):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
　Tian Qi,Jiang Ningyi,Zheng Li.Therapeutic effect of fine individual 131I treatment on Graves disease hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
[4]杨珂,唐波,于夕荣,等.甲状腺癌131i治疗病房的辐射屏蔽计算与评价[J].国际放射医学核医学杂志,2015,39(5):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
　yang ke,tang bo,yu xirong,et al.shielding calculation and assessment in 131i therapy for thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
[5]徐蓉生,梅艳,赵力威,等.B超引导下术中125I粒子植入治疗晚期胰腺癌的疗效评价[J].国际放射医学核医学杂志,2016,40(6):424.[doi:10.3760/cma.j.issn.1673-4114.2016.06.005]
　Xu Rongsheng,Mei Yan,Zhao Liwei,et al.Evaluation of 125I particle implantation in the treatment of patients with advanced pancreatic neoplasms using B ultrasound-guided surgery[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):424.[doi:10.3760/cma.j.issn.1673-4114.2016.06.005]
[6]王越,晋建华,李思进,等.甲状腺24h摄碘率与131I治疗Graves甲亢疗效相关性研究[J].国际放射医学核医学杂志,2015,39(6):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
　Wang Yue,Jin Jianhua,Li Sijin,et al.Correlation between thyroid 24 h of radioactive iodine uptake and clinical efficacy of 131I therapy for Graves’ hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
[7]郭坤,高蕊,于燕,等.表皮生长因子受体基因表达与甲状腺功能亢进症131I治疗预后的关系[J].国际放射医学核医学杂志,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
　Guo Kun,Gao Rui,Yu Yan,et al.The relationship between epidermal growth factor receptor mRNA expression and the efficacv of 131I treatment in hyperthyroidism patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
[8]胡小春,蒋宁一,李敬彦,等.硒对经131I治疗Graves病患者血清甲状腺过氧化物酶抗体水平的影响[J].国际放射医学核医学杂志,2015,39(2):140.[doi:10.3760/cma.j.issn.1673-4114.2015.02.008]
　Hu Xiaochun,Jiang Ningyi,Li Jingyan,et al.Effect of additional selenium on the levels of serum thyroid peroxidase antibody in patients with Graves disease treated with 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):140.[doi:10.3760/cma.j.issn.1673-4114.2015.02.008]
[9]杨翠红,刘金剑,褚丽萍,等.125I标记注射用干扰素α2b(假单胞菌)研究雾化吸入与肌肉注射的代谢及组织分布差异[J].国际放射医学核医学杂志,2015,39(3):191.[doi:10.3760/cma.j.issn.1673-4114.2015.03.001]
　Yang Cuihong,Liu Jinjian,Chu Liping,et al.Pharmacokinetics and tissue distribution of interferon α2b（Pseudomonas putida）administered via atomization inhalation and intramuscular injection by 125I labeling[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):191.[doi:10.3760/cma.j.issn.1673-4114.2015.03.001]
[10]陈雪梅,周树云,范源,等.表没食子儿茶素没食子酸酯对131I辐射损伤所致甲减大鼠模型抗氧化体系的保护作用[J].国际放射医学核医学杂志,2015,39(4):311.[doi:10.3760/cma.j.issn.1673-4114.2015.04.009]
　Chen Xuemei,Zhou Shuyun,Fan Yuan,et al.Protection of antioxidant system of EGCG on the thyroid in rat model from 131I radiation damage[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):311.[doi:10.3760/cma.j.issn.1673-4114.2015.04.009]
[11]赵腾,梁军,林岩松.131I治疗前刺激性Tg在分化型甲状腺癌风险评估及治疗决策中的意义[J].国际放射医学核医学杂志,2015,39(1):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
　Zhao Teng,Liang Jun,Lin Yansong.The role of preablative stimulated thyroglobulin in guiding risk estimation and therapeutic decisions of differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
[12]钞卫光,张晶,陆克义.分化型甲状腺癌腹盆部131I显像假阳性分析[J].国际放射医学核医学杂志,2017,41(5):370.[doi:10.3760/cma.j.issn.1673-4114.2017.05.012]
　Chao Weiguang,Zhang Jing,Lu Keyi.Analysis of differentiated thyroid cancer false-positive uptake in abdominal cavity and pelvic cavity on radioiodine whole-body scan[J].International Journal of Radiation Medicine and Nuclear Medicine,2017,41(6):370.[doi:10.3760/cma.j.issn.1673-4114.2017.05.012]
[13]孔维静,徐颖.综合干预措施下评估首次131I清甲治疗对分化型甲状腺癌患者唾液腺的慢性损伤[J].国际放射医学核医学杂志,2018,(1):30.[doi:10.3760/cma.j.issn.1673-4114.2018.01.006]
　Kong Weijing,Xu Ying.Assessment of the chronic injury of salivary glands in patients with differentiated thyroid cancer who underwent comprehensive intervention measures with first 131I clearing therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(6):30.[doi:10.3760/cma.j.issn.1673-4114.2018.01.006]
[14]南楠,朱小华.分化型甲状腺癌131I显像假阳性的原因分析[J].国际放射医学核医学杂志,2018,(1):62.[doi:10.3760/cma.j.issn.1673-4114.2018.01.012]
　Nan Nan,Zhu Xiaohua.Analysis of the false positive findings on 131I whole-body scan in differentiated thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(6):62.[doi:10.3760/cma.j.issn.1673-4114.2018.01.012]

备注/Memo

备注/Memo:
收稿日期:2016-06-29。
通讯作者:刘保平,Email:liubp5000@sina.com
更新日期/Last Update: 1900-01-01